Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production. The new offering will provide seamless access to Asimov’s CHO Edge cell line development platform, Cytiva's HyClone media and feed solutions, and Cytiva’s Fast Trak process development services.

Asimov是一家致力于推进治疗药物设计与制造的合成生物学公司，正在与全球生命科学领域的领导者Cytiva合作，为客户提供优化生物制品生产的综合解决方案。这一全新服务将无缝对接Asimov的CHO Edge细胞系开发平台、Cytiva的HyClone培养基和补料解决方案，以及Cytiva的Fast Trak工艺开发服务。

Together, these services and technologies enable the expression and development of protein biologics, including complex modalities, that hold the potential to significantly impact human health..

这些服务和技术共同促进了蛋白质生物药物的表达与发展，包括那些具有显著影响人类健康潜力的复杂模式。

Alec Nielsen, co-founder and CEO of Asimov, says: “Central to this collaboration is the extensive optimization of our CHO Edge System in Cytiva’s HyClone media and feed, enabling high titer across biologic formats. By integrating a robust cell line development capability into Cytiva’s established biomanufacturing technologies, we can enhance customers’ production efficiency and accelerate their development timelines for critical therapeutics.”.

Asimov联合创始人兼首席执行官 Alec Nielsen 表示：“此次合作的核心是在Cytiva的HyClone培养基和饲料中对我们的CHO Edge系统进行广泛优化，从而在各种生物制品形式中实现高滴度。通过将强大的细胞系开发能力整合到Cytiva成熟的生物制造技术中，我们可以提高客户的生产效率，并加速其关键治疗药物的开发时间。”

Ludovic Brellier, President, Hardware Solutions, Cytiva says: “We’re two innovative players coming together to provide the technologies and services our customers need to accelerate the development of advanced therapeutics. By combining Asimov’s integrated suite of cells, genetic tools, AI models, and software with our extensive process development services, customers will have a cohesive path from development to commercialization.”.

Cytiva硬件解决方案总裁Ludovic Brellier表示：“我们是两家创新企业联手，为客户提供加速先进治疗开发所需的技术和服务。通过将Asimov集成的细胞、基因工具、人工智能模型和软件套件与我们广泛的工艺开发服务相结合，客户将拥有一条从开发到商业化的连贯路径。”

Cell line development technology has improved substantially over the years, but the majority of complex biologics are still produced using relatively low-titer cell lines. Asimov’s CHO Edge System, which enables molecule-specific expression optimization, significantly reduces the risk of low titer cell lines and enables customers to routinely achieve 7-11 g/L clones across biologic modalities.

多年来，细胞系开发技术已经有了显著的进步，但大多数复杂的生物制品仍然使用相对低滴度的细胞系进行生产。Asimov 的 CHO Edge 系统通过实现分子特异性表达优化，大幅降低了低滴度细胞系的风险，并使客户能够常规实现跨生物模式的 7-11 g/L 克隆产量。

The system leverages a GS knock-out CHO host, a hyperactive transposase, a library of genetic elements, and advanced computational tools to design and optimize the vector. When paired with Cytiva’s Fast Trak process development services and HyClone media and feed, the new offering provides customers with a full suite of solutions from cell line development; cell culture media optimization; analytical and stability testing; and scaling to GMP production..

该系统利用了GS敲除的CHO宿主、高活性转座酶、遗传元件库以及先进的计算工具来设计和优化载体。结合Cytiva的Fast Trak工艺开发服务以及HyClone培养基和补料，这一新方案为客户提供了一整套从细胞系开发、细胞培养基优化、分析与稳定性测试到GMP生产的全流程解决方案。

Learn more about Cytiva’s Fast Trak process development services and HyClone media and feed.

了解有关Cytiva的Fast Trak工艺开发服务和HyClone培养基及补料的更多信息。

Here’s more information on Asimov’s CHO Edge cell line development platform.

以下是关于阿西莫夫的CHO Edge细胞系开发平台的更多信息。

Cytiva, the drop logo, HyClone and Fast Trak are trademarks of Global Life Sciences USA LLC or an affiliate doing business as Cytiva.

Cytiva、水滴形标志、HyClone 和 Fast Trak 是 Global Life Sciences USA LLC 或其以 Cytiva 名义开展业务的关联公司的商标。

About Asimov

关于阿西莫夫

Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations..

阿西莫夫的使命是提升人类设计生命系统的能力，推动具有巨大社会效益的生物技术发展。该公司正在开发一个从细胞到软件的合成生物学平台，通过产品、服务和合作相结合的方式，设计和制造下一代治疗药物，包括生物制品、细胞/基因疗法以及RNA。

Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com..

公司由麻省理工学院和波士顿大学的生物工程师创立，总部位于波士顿，已从包括Andreessen Horowitz、CPP Investments、Horizons Ventures和富达管理研究公司在内的顶级机构投资者处筹集了超过2亿美元。欲了解更多信息，请访问www.asimov.com。

Media contact:

媒体联系人:

Alec Nielsen

亚历克·尼尔森

media@asimov.com

媒体@阿西莫夫.com

About Cytiva

关于Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.

在Cytiva，我们的使命是推动和加速治疗药物的开发。我们在40多个国家拥有15,000名员工，致力于运用我们的专业知识和才能，为客户提供更高的灵活性、产能和效率。我们广泛而深入的工具与技术组合、全球规模以及业内领先的服务，为从发现到交付的各个环节提供了关键支持，客户涵盖研究人员、新兴生物技术公司、大规模生物制药企业以及合同制造商。

Learn more at cytiva.com.

请访问 cytiva.com 了解更多信息。

Media contact:

媒体联系人：

Tania Kimball

谭妮娅·金博尔

tania.kimball@cytiva.com

塔尼亚·金鲍尔@思拓凡.com

Source: cytivalifesciences.com

来源：cytivalifesciences.com